Journal of Health System Research
مجله تحقیقات نظام سلامت
J Health Syst Res
Medical Sciences
http://hsr.mui.ac.ir
1
admin
2783-4093
2322-5564
10.48305
14
8888
13
fa
jalali
1405
1
1
gregorian
2026
4
1
22
1
online
1
fulltext
fa
شناسایی و اولویتبندی نقشآفرینان و ذینفعان در درمان بیماری شبکیه نوزادان نارس در ایران: آغازی برای یک تحول
Identification and Prioritization of Actors and Stakeholders in the Treatment of Retinopathy of Prematurity in Iran: The Beginning of a Transformation
آموزش بهداشت و ارتقاء سلامت
education health and promotion
پژوهشي
Research
<div style="text-align: justify;"><span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">مقدمه:</span></span></span></b><b> </b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">حضور نقشآفرینان و ذینفعان مختلف با علایق گوناگون و انتظارات متفاوت در اجرای پروژهها، از جمله مسایلی است که مدیران پروژه را در مدیریت صحیح ذینفعان با چالش جدی روبهرو میسازد. پژوهش حاضر به منظور شناسایی و اولویتبندی نقشآفرینان و ذینفعان در حوزه درمان بیماری شبکیه نوزادان نارس (</span></span></span><span dir="LTR" style="font-size:9.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">ROP</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> یا </span></span></span><span dir="LTR" style="font-size:9.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Retinopathy of prematurity</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">) و همچنین، آشنایی با میزان تعهد و تأثیرگذاری آنان در درمان این بیماری انجام شد</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">.</span></span></span><span dir="LTR" style="font-size:10.0pt"><span bold="" new="" roman="" style="font-family:" times=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="AR-SA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">روشها</span></span></span></b><span lang="AR-SA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">: </span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">این مطالعه به روش توصیفی- تطبیقی و بر اساس مدل 8 مرحلهای تحلیل ذینفعان </span></span></span><span dir="LTR" style="font-size:9.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Kammi Schmeer</span></span></span><span style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> طی 4 مرحله اجرایی، با شناسایی اولیه ذینفعان با مطالعات کتابخانهای، مصاحبه باز و پس از آن از طریق انتشار پرسشنامه الکترونیکی با نمونهگیری هدفمند و در دسترس بین 54 خبره در فرایند درمانی در سراسر کشور انجام گردید. دادهها در نرمافزار </span></span></span><span dir="LTR" style="font-size:9.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">SPSS</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> مورد تجزیه و تحلیل قرار گرفت</span></span></span><span lang="AR-SA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">.</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">یافتهها:</span></span></span></b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> اجرای تحقیق منجر به شناسایی 4 گروه از ذینفعان اصلی مدیریت و سیاستگذاری سلامت، پشتیبانی و اجرایی، ارایه دهندگان خدمات درمانی، نوزاد و والدین و 23 زیرگروه در کلیه مراحل درمانی گردید. در ادامه، میزان تعهد به ایجاد تغییرات و تأثیرگذاری هر یک از گروههای چهارگانه مورد بررسی قرار گرفت. در نهایت، راهکارهایی به منظور پیشبرد اهداف پژوهشی در درمان این بیماری ارایه گردید.</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">نتیجهگیری:</span></span></span></b><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> طیف وسیع و تنوع ذینفعان، نشان دهنده پیچیدگیهای فرایند درمان </span></span></span><span dir="LTR" style="font-size:9.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">ROP</span></span></span><span lang="FA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black"> در ایران است. این موضوع نیاز به همکاری و مشارکت را به عنوان یک اقدام حیاتی به منظور طراحی چارچوب نظام ملی مراقبتی برای انجام مراحل مختلف غربالگری، شناسایی و درمان این بیماری برجسته میسازد</span></span></span><span lang="AR-SA" style="font-size:10.0pt"><span b="" style="font-family:" zar=""><span style="color:black">.</span></span></span><span dir="LTR" style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:107%"><span sans-serif="" style="font-family:Calibri,"><span style="font-size:12.0pt"><span style="line-height:107%"><span style="color:black"></span></span></span></span></span></span></div>
<div style="text-align: justify;"><span style="font-size:11pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Background</span></span></span></b><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">:</span></span></span></b> <span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">The presence of different actors and stakeholders with different interests and expectations in project implementation is one of the issues that presents project managers with serious challenges in managing stakeholders properly. This study was conducted to identify and prioritize the actors and stakeholders in the field of treating retinopathy of prematurity (ROP), as well as to learn about the level of commitment and effectiveness of the stakeholders in treating this disease</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">.</span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Methods:</span></span></span></b> <span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">The present study was conducted in a descriptive-comparative manner and based on the 8-step model of stakeholder analysis using "Kammi Schmeer" method in 4 implementation stages, with initial identification of stakeholders through library studies, open interviews, and then through the distribution of an electronic questionnaire with purposive and convenience sampling among 54 experts in the treatment process in Iran. The data were analyzed using SPSS software</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">.</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Findings:</span></span></span></b> <span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">The implementation of the research led to the identification of 4 groups of main stakeholders including health management and policymaking, support and implementation, medical service providers, infants and parents, and 23 subgroups in all treatment stages. Further, the level of commitment to creating change and the effectiveness of each of the four groups were investigated. Finally, strategies were presented to advance research goals in the treatment of this disease</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">.</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Conclusion:</span></span></span></b> <span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">The wide diversity of stakeholders reflects the complexities of the treatment process for ROP in Iran. It also highlights the need for collaboration and partnership as a critical step in designing a national care framework for the various stages of screening, identification, and treatment of this disease</span></span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">.</span></span></span></span></span></span></span></span></div>
بیماری شبکیه نوزادان نارس, ذینفعان, سیاست سلامت, مراقبت از نوزادان, Kammi Schmeer, غربالگری, تشخیص
Retinopathy of prematurity, Stakeholder Analysis, Health Policy, Neonatal Care, Kammi Schmeer, Screening and Diagnosis
165
176
http://hsr.mui.ac.ir/browse.php?a_code=A-10-790-2&slc_lang=fa&sid=1
Maryam
Mollabagher
مریم
ملاباقر
maryam_mollabagher@modares.ac.ir